期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

18F-FDG PET/CT定位诊断异位分泌促肾上腺皮质激素肿瘤的价值 被引量：3

The diagnostic value of 18F-FDG PET/CT in the localization of ectopic adrenocorticotrophic hormone-secreting tumors
原文传递
导出
摘要 目的 探讨18 F-脱氧葡萄糖（FDG）PET/CT定位诊断异位分泌促肾上腺皮质激素（ACTH）肿瘤的应用价值.方法 疑诊异位分泌ACTH患者共7例,其中男4例,女3例,年龄27～63岁.7例患者均根据临床症状、生化指标或岩下窦采血结果诊断为异位ACTH综合征,同时进行了头颅MR、胸腹部CT、腹部B超及18F-FDG PET/CT检查,以探查原发病灶,并对发现的病灶进行大小及最大标准摄取值（SUVmax）的测量.结果 7例患者中3例经18F-FDG PET/CT找到原发病灶,病灶大小分别为1.1 cm×1.0 cm、1.5 cm×1.1 cm、1.6 cm×1.5 cm,SUVmax值分别为9.4,6.4和12.0.随后对患者进行了肿瘤切除,病理检查结果分别为胸腺瘤、肺部类癌及纵隔类癌.原发灶检出率为3/7.结论 18F-FDG PET/CT在定位诊断异位分泌ACTH肿瘤中具有一定价值. Objective To investigate the diagnostic value of 18F-fluorodeoxyglucose （FDG） PET/CT in the localization of ectopic adrenocorticotrophic hormone （ ACTH）-secreting tumors. Methods Seven patients with ectopic ACTH syndrome （confirmed by clinical symptom, biochemical data or bilateral simultaneous inferior petrosal sinus sampling） were included, 4 males and 3 females with age ranged 27-63 years old.All patients were examined with head MR, chest and abdomen CT, abdomen ultrasonography, and whole body 18F-FDG PET/CT. Location, size, and the maximum standardized uptake value （SUVmax） of the tumor were measured. Results 18 F-FDG PET/CT detected three ectopic ACTH-secreting tumors with the sizes 1. 1 cm×1.0 cm （SUVmax =9.4）, 1.5 cm×1.1cm （SUVmax =6.4）, and 1.6 cm ×1.5 cm （SUVmax =12.0）. The pathological findings of the three tumors were thymoma, lung carcinoid, and mediastinal carcinoid respectively. Conclusion 18 F-FDG PET/CT may help the localization of ecto pic ACTH-secreting tumors .
作者 张敏 徐昊平 李彪
机构地区 上海交通大学医学院附属瑞金医院核医学科
出处 《中华核医学杂志》 CAS CSCD 北大核心 2010年第5期329-332,共4页 Chinese Journal of Nuclear Medicine
基金 基金项目：上海市重点学科建设项目（S30203）
关键词 神经内分泌瘤 促肾上腺皮质激素 体层摄影术 发射型计算机 体层摄影术 X线计算机 脱氧葡萄糖 Neuroendocrine tumors Adrenocorticotrophic hormone Tomography,emission-computed Tomography, X-ray computed Deoxyglucose
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献10

  • 1Reimondo G,Paciotti P,Minetto M,et al.The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome.Clin Endocrinol,2003,58:718-724.
  • 2毕宇芳,宁光,陈宇红,叶蕾,苏颋为,孙首悦,顾卫琼,杨军,朱娜,姜蕾,刘建民,李小英,王卫庆.17例异位ACTH综合征的前瞻性研究[J].上海交通大学学报（医学版）,2006,26(1):43-47. 被引量：16
  • 3Pacak K,Ilias I,Chen CC,et al.The role of ^18F flourodeoxyglucose positron emission tomography and ^111 In-diethylenetriaminepentaacetate-D-phe-pentreotide scintigraphy in the localisation of ectopic adrenocorticotropin-secreting tumours causing Cushing's syndrome.J Clin Endocrinol Metab,2004,89; 2214-2221.
  • 4王卫庆,赵红燕,陈瑛,孙首悦,毕宇芳,汤正义,赵咏桔,姚晓虹,方文强,陈中元,陈克敏,金晓龙,胡仁明,罗敏,宁光.胸腺类癌致异位ACTH综合征[J].中华内分泌代谢杂志,2003,19(6):445-448. 被引量：22
  • 5吕朝晖,陆菊明,金文胜,窦京涛,母义明,潘长玉.异位ACTH综合征和库欣病伴低血钾临床特点的比较[J].中华内分泌代谢杂志,2004,20(5):438-440. 被引量：25
  • 6Chong S,Lee KS,Kim BT,et al.Integrated PET/CT of Pulmonary neuroendocrine tumors:diagnostic and prognostic implications.Am J Roentgenol,2007,188:1223-1231.
  • 7Markou A,Manning P,Kaya B,et al.^18F-fluoro-2-deoxy-D-glucose (^18F-FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome.Eur J Endocrinol,2005,152:521-525.
  • 8Hoegerle S,Altehoefer C,Ghanem N,et al.Whole-body ^18F dopa PET for detection of gastrointestinal carcinoid tumors.Radiology,2001,220:373-380.
  • 9Sundin A,Eriksson B,Bergstrom M,et al.Demonstration of ^11C-5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.Nucl Med Biol,2000,27:33-41.
  • 10Arbizu J,Rodriguez-Fraile M,Dominguez-Prado I,et al.Whole body ^18F-fluoro-L-dopa PET-CT:a useful tool for location and surgical guidance in primary carcinoid tumours.Eur J Nucl Med Mol Imaging,2008,35:1577.

二级参考文献29

  • 1吕朝晖,陆菊明,金文胜,窦京涛,母义明,潘长玉.异位ACTH综合征和库欣病伴低血钾临床特点的比较[J].中华内分泌代谢杂志,2004,20(5):438-440. 被引量：25
  • 2崔贤德,王圣祥,施钰,罗邦尧,朱家颖,冯月明,许曼音.皮质醇增多症诊断评估──附113例临床分析[J].上海医学,1994,17(5):272-274. 被引量：10
  • 3[2]Wajchenberg BL,Mendonca BB,Liberman B,et al.Ectopic adrenocorticotropic hormone syndrome[J].Endocr Rev,1994,15(6):752-786.
  • 4[4]Aniszewski JP,Young WF,Thompson GB,et al.Cushing syndrome due to ectopic adrenocorticotropic hormone secretion[J].World J Surg,2001,25(7):934-940.
  • 5[5]Reimondo G,Paciotti P,Minetto M,et al.The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome[J].Clin Endocrinol,2003,58(6):718-724.
  • 6[6]Dall'Asta C,Santambrogio L,Castellani M,et al.Difficulties in diagnosis and treatment of ectopic ACTH-producing tumors of the chest[J].Eur J Cardiothorac Surg.,2002,21(1):149-151.
  • 7[9]Wajchenberg BL,Mendonca BB,Liberman B,et al.Ectopic adrenocorticotropic hormone syndrome[J]Endocr Rev,1994,15(6):752-787.
  • 8[10]Illias I,Torpy DJ,Pacak K,et al.Cushing's syndrome due to ectopic corticotropin secretion:twenty years' experience at the national institutes of health[J].J Clin Endocrinol Metab,2005,90(8):4955-4962.
  • 9[11]Flack MR,Oldfield EH,Cutler GB Jr,et al.Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome[J].Ann Intern Med,1992,116(3):211-217.
  • 10[12]Doppman JL,Oldfield EH,Krudy AG,et al.Petrosal sinus sampling for Cushing syndrome:anatomical and technical considerations.Work in progress[J].Radiology,1984,150(1):99-103.

共引文献51

同被引文献39

  • 1Beuschlein F,Hammer GD.Ectopic pro-opiomelanocor tin syndrome[J].Endocrinol Metab Clin North Am,2002,31(1):191-234.
  • 2Comi RJ,Gorden P.Long-term medical treatment of ectopic ACTH syndrome[J].South Med J,1998,91(11):1014-1018.
  • 3Nieman I,Billet B,Findling J,el a1.The diagnosis of Cushing’s syndrome:An Endoerine Sociaty Clinical Practice Guideline[J].J Clin Endocrinol Metab,2008,93(5):1526-1540.
  • 4Stewart PM.The adrenal cortex.In:Kronenberg HM,Melmed S.eds.Williams Textbook of Endocr i nolog y.11th ed[M].Philadclphia:Saunders/Elsvier,2008:445-504.
  • 5Biller B,Grossman A,Stewart P,et a1.Treatment of corticotropin-dependent Cushing’s syndrome:A consensus statement[J].J Clin Endocrinol Metab,2008,93(7):2454-2462.
  • 6Von Wender K,MuIIer OA,StaIIa GK.Somatostatin anaIogs in ectopic corticotropin production[J].MetaboIism,1996,45(SuppI1):129-131.
  • 7Matte J,Roufosse F,Rocmans P,et aI.Ectopic Cushing's syndrome and puImonary carcinoid tumor identified by111In-DTPA-D-PheI octreotide[J].Postgrad Med J,1998,74:108-114.
  • 8Woodhouse NJY,Dagogo-Jack S,Ahmed M,et al.Acute and Iongterm effects of octreotide in patients with ACTH dependent Cushing's syndrome[J].Am J Med,1997,95(3):305-308.
  • 9Zemskova MS,Nylen ES,Patronas NJ,et al.Diagnostic accuracy of ehromogranin A and calcitonin precursors measurements for the dis-rimination of eetopie ACTH secretion from Cushing’s disease[J].J Clin Endocrinol Metab,2009,94(8):2962-2965.
  • 10Donadille B,Groussin L,Waintrop L,et al.Management of Cushing's syndrome due to ectopic adrenocor ticotropin secretion with1,ortho-1,para'-dichloro-diphe-nyl-dichloro-ethane:findings in23patients from a single center[J].J Clin Endocrinol Metab,2010,95(2):537-544.

引证文献3

二级引证文献9

中华核医学杂志
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部